RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

SBRT Versus Surgical Resection for Small HCC

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07381660, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. For patients with recurrent disease, recurrence must occur at least 1 year after prior curative treatments;

    Inclusion criterion 6

    Previously treated patients must not have received systemic therapy within 6 months before enrollment;

    Inclusion criterion 7

    A normal liver volume of ≥700 cc, with an estimated future liver remnant volume of >40% after resection;

    Inclusion criterion 9

  3. A Karnofsky performance-status score of ≥90;

    Inclusion criterion 10

  4. In previously treated patients, tumor size must be assessed according to RECIST version 1.1 at enrollment;

    Inclusion criterion 8

  5. Pregnancy or breastfeeding;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07381660, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 to 75 years, with no restriction on sex;
  • Clinically or pathologically diagnosed hepatocellular carcinoma, according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 edition);
  • A solitary tumor with a maximum diameter of ≤5 cm, for which treatment is indicated;
  • No radiologic evidence of macrovascular invasion, distant metastasis, or lymph node metastasis;
  • Treatment-naïve or previously treated patients are eligible, provided that they are deemed suitable for both surgical resection and radiotherapy by a multidisciplinary team (MDT) and do not require concomitant systemic therapy at enrollment;
  • For patients with recurrent disease, recurrence must occur at least 1 year after prior curative treatments;
  • Previously treated patients must not have received systemic therapy within 6 months before enrollment;
  • In previously treated patients, tumor size must be assessed according to RECIST version 1.1 at enrollment;
  • A normal liver volume of ≥700 cc, with an estimated future liver remnant volume of >40% after resection;
  • A Karnofsky performance-status score of ≥90;
  • Child-Pugh class A liver function;
  • An estimated life expectancy of more than 6 months;
  • Adequate organ function, defined as follows: white-cell count ≥3.5×10⁹/L, absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥75.0×10⁹/L, hemoglobin ≥90 g/L; serum albumin ≥28 g/L; total bilirubin ≤1.5 times the upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase ≤2.5 times the ULN; serum creatinine ≤1.5 times the ULN or creatinine clearance >60 mL per minute; and no severe concomitant organic disease;
  • The ability to understand the study procedures and to provide written informed consent before the initiation of any study-specific procedures, with agreement to receive treatment and follow-up according to the study protocol.

Exclusion Criteria:

  • Severe dysfunction of major organs, including the heart, lungs, or kidneys; active infection other than viral hepatitis; or other serious concomitant conditions that preclude tolerance of either surgery or radiotherapy;
  • Contraindications to surgical resection or radiotherapy;
  • A history of other malignant tumors, with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, or previously cured prostate cancer, nasopharyngeal carcinoma, breast cancer, or early-stage laryngeal cancer;
  • A history of multiple abdominal surgeries or liver or other solid-organ transplantation;
  • Previous radiotherapy to the upper abdomen;
  • Pregnancy or breastfeeding;
  • Any other condition that may interfere with patient enrollment or the assessment of study outcomes;
  • Refusal to comply with the follow-up requirements of the study protocol or refusal to provide written informed consent.

Quoted from ClinicalTrials.gov, NCT07381660, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07381660, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07381660